High risk factors related to central lymph node metastasis in papillary thyroid microcarcinoma

doi:10.3760/cma.j.issn.1673-422X.2016.01.012

Abstract

Abstract: In recent years, a large number of studies have found that central lymph node metastasis of the papillary thyroid microcarcinoma (PTMC) is significantly related with some risk factors. These high risk factors include age below 45 years old, BRAF gene mutation, vascular epithelial growth factorC high expression, tumor diameter≥5 mm, multifocal and bilateral tumor, thyroid capsule invasion and so on. These high risk factors involve in disease process, and interact with each other. The studies of the high risk factors can help us to predict the risk of central lymph node metastasis in the patients with PTMC, thus to effectively guide the patients′ treatment.

Key words: Thyroid neoplasms, Lymph nodes, Risk factors

Li Yao, Wang Shengying. High risk factors related to central lymph node metastasis in papillary thyroid microcarcinoma[J]. Journal of International Oncology, 2016, 43(1): 42-44.

References

［1］ Soares P, Celestino R, Gaspar da Rocha A, et al. Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic?［J］. Int J Surg Pathol, 2014, 22(2): 113-119. DOI:10.1177/1066896913517394. ［2］ Kim YS. Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma［J］. Otolaryngol Head Neck Surg, 2012, 147(1): 15-19. DOI:10.1177/0194599812439277. ［3］ Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid microcarcinoma with bilateral involvement and central lymph node metastasis: a retrospective study［J］. World J Surg Oncol, 2012, 10: 67-67. DOI: 10.1186/1477-7819-10-67. ［4］ Lu ZZ, Zhang Y, Wei SF, et al. Outcome of papillary thyroid microcarcinoma: study of 1 990 cases［J］. Mol Clin Oncol, 2015, 3(3): 672676. DOI:10.3892/mco.2015.495. ［5］ Li X, AbdelMageed AB, Kandil E. BRAF mutation in papillary thyroid carcinoma［J］. Int J Clin Exp Med, 2012, 5(4): 310-315. ［6］ Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma［J］. Ann Surg Oncol, 2010, 7(12): 3294-3300. DOI:10.1245/s10434-010-1129-6. ［7］ Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?［J］. Front Endocrinol (Lausanne), 2012, 3: 33-33. DOI:10.3389/fendo.2012.00033. ［8］ Yan LI, Li LI, Li Q, et al. Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer［J］. Exp Ther Med, 2015, 9(6): 2195-2201. DOI:10.3892/etm.2015.2409. ［9］ Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1 066 patients［J］. J Clin Endocrinol Metab, 2012, 97(4): 1250-1257. DOI:10.1210/jc.2011-1546. ［10］ Zhang LY, Liu ZW, Liu YW, et al. Risk factors for nodal metastasis in cN0 papillary thyroid microcarcinoma［J］. Asian Pac J Cancer Prev, 2015, 16(8): 3361-3363. ［11］ Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7mm tumor size［J］. World J Surg, 2011, 35(2): 318-323. DOI:10.1007/s00268-010-0886-5. ［12］ Liu Z, Wang L, Yi P, et al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a metaanalysis［J］. Int J Clin Exp Pathol, 2014: 7(3): 932-937. ［13］ Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma［J］. Yonsei Med J, 2012, 53(5): 924-930. DOI:10.3349/ymj.2012.53.5.924. ［14］ Chung YJ, Lee JS, Park SY, et al. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma［J］. Histopathology, 2013, 62(4): 578-588. DOI:10.1111/his.12025. ［15］ Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area［J］. World J Surg, 2010, 34(6): 1214-1221. DOI:10.1007/s00268-009-0375-x. ［16］ Ardito G, Revelli L, Giustozzi E, et al. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy［J］. Clin Nucl Med, 2013, 38(1): 25-28. DOI: 10.1097/RLU.0b013e318279bc65. ［17］ Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma［J］. Ann Surg Oncol, 2013, 20(3): 746752. DOI: 10.1245/s1043401226542. ［18］ So YK, Kim MW, Son YI. Multifocality and bilaterality of papillary thyroid microcarcinoma［J］. Clin Exp Otorhinolaryngol, 2015, 8(2): 174-178. DOI:10.3342/ceo.2015.8.2.174. ［19］ Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma［J］. Int J Clin Exp Pathol, 2014, 7(9): 6199-6205. ［20］ Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5 768 patients with average 10year followup［J］. World J Surg, 2012, 36(6): 12741278. DOI:10.1007/s0026801214235. ［21］ Wan HF, Zhang B, Yan DG, et al. The BRAFT1799A mutation is not associated with occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma［J］. Asian Pac J Cancer Prev, 2015, 16(7): 2947-2951. ［22］ Ma YJ, Deng XL, Li HQ. BRAF (V600E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: a meta-analysis［J］. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(4): 591599. DOI:10.1007/s11596-015-1476-4. ［23］ Connor MP, Wells D, Schmalbach CE. Variables predictive of bilateral occult papillary microcarcinoma following total thyroidectomy［J］. Otolaryngol Head Neck Surg, 2011, 144(2): 210-215. DOI:10.1177/0194599810391616.

[1]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[2]	Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin. Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer [J]. Journal of International Oncology, 2024, 51(1): 43-49.
[3]	Deng Juanjun, Zhao Dayong, Li Miao. Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2023, 50(9): 564-568.
[4]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui. Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway [J]. Journal of International Oncology, 2023, 50(7): 398-406.
[5]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Jiao Panpan, Xue Lijuan, Zhan Juan. Risk factors and predictors of immune-related adverse events induced by immune checkpoint inhibitors [J]. Journal of International Oncology, 2023, 50(12): 739-744.
[7]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[8]	Zhang Yan, Pan Lei, Liu Shuting. Establishment of an efficacy prediction model for gefitinib in non-small cell lung cancer patients based on ABCB1 and ABCG2 gene polymorphisms [J]. Journal of International Oncology, 2022, 49(6): 327-333.
[9]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[10]	Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong. Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma [J]. Journal of International Oncology, 2022, 49(10): 581-585.
[11]	Wu Yuping, Zhang Xiaoyu, Lu Keyi. Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment [J]. Journal of International Oncology, 2021, 48(9): 560-563.
[12]	Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong. BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis [J]. Journal of International Oncology, 2021, 48(8): 463-472.
[13]	Wang Hui, Xia Rong, Wei Qingwen, Wan Yixin. Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer [J]. Journal of International Oncology, 2021, 48(5): 296-301.
[14]	Hou Xiaofeng, Xue Jincai, Tian Youxin, Liu Qinjiang. Diagnosis and surgical treatment of differentiated thyroid carcinoma in 40 years [J]. Journal of International Oncology, 2020, 47(8): 449-456.
[15]	Cheng Hu, Liu Mingkui, Chen Tianping. Effects of lncRNA AFAP1-AS1 on proliferation and invasion of thyroid cancer cells and its mechanisms [J]. Journal of International Oncology, 2020, 47(6): 327-332.